论文部分内容阅读
目的:评价脱氧核苷酸钠短期大剂量干预实体肿瘤化疗所引起骨髓抑制及肝脏损伤的有效性及安全性,并评价脱氧核苷酸钠对肿瘤细胞生长的影响。方法:86例肺癌、胃癌、结直肠癌、肝癌患者,随机分为对照组和观察组各43例。两组均采用常规化疗方案,观察组在化疗基础上给予脱氧核苷酸钠200 mg,ivd,qd。化疗后评价两组患者骨髓抑制、肝功能和体质量情况。结果:观察组与对照组总有效率分别为47.5%,44.9%,差异无统计学意义(P>0.05)。观察组患者III~IV度骨髓抑制发生率为20.0%,明显低于对照组的58.5%(P<0.05);CD3+、CD4+、NK细胞水平均高于对照组(P<0.01)。两组肝功能异常发生率分别为27.5%、65.8%,差异有统计学意义(P<0.01)。化疗后,观察组患者体质量明显高于对照组(P<0.05)。结论:脱氧核苷酸可以减轻化疗所导致的骨髓抑制及肝功能的损伤,促进患者体质量恢复。
OBJECTIVE: To evaluate the efficacy and safety of short-term large doses of deoxynucleotide sodium in the treatment of bone marrow suppression and liver injury caused by solid tumor chemotherapy, and to evaluate the effect of deoxynucleotide sodium on tumor cell growth. Methods: Eighty-six patients with lung cancer, gastric cancer, colorectal cancer, and liver cancer were randomly divided into control group and observation group. Both groups were treated with conventional chemotherapy. The observation group was given deoxynucleotide sodium 200 mg, ivd, qd on the basis of chemotherapy. After chemotherapy, bone marrow suppression, liver function and body weight were evaluated in both groups. Results: The total effective rates of the observation group and the control group were 47.5% and 44.9%, respectively, and the difference was not statistically significant (P>0.05). The incidence of myelosuppression in grade III to IV in the observation group was 20.0%, which was significantly lower than that in the control group (58.5%) (P<0.05). The levels of CD3+, CD4+, and NK cells were higher in the observation group than in the control group (P<0.01). The incidence of abnormal liver function in the two groups was 27.5% and 65.8%, respectively, and the difference was statistically significant (P<0.01). After chemotherapy, the body weight of the observation group was significantly higher than that of the control group (P<0.05). Conclusion: Deoxynucleotide can reduce bone marrow suppression and liver function damage caused by chemotherapy, and promote the recovery of body weight.